GlassScriptPhysician profile
Karsten G Tucker
NPI 1396852240
$3,256.34
in general payments reported to CMS, 2019-2025
29 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $302 · 2021: $230 · 2022: $513 · 2023: $838 · 2024: $562 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.50 | 2023-2025 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $372.56 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $353.82 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $268.57 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $238.19 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $234.32 | 2019-2025 | Krystexxa, Evenity, Repatha |
| Merck Sharp & Dohme LLC | $200.61 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $192.70 | 2022-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.45 | 2019-2022 | |
| Exact Sciences Corporation | $118.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $108.27 | 2022 | |
| Amarin Pharma, INC. | $87.56 | 2019-2020 | |
| Inspire Medical Systems, INC. | $44.29 | 2025 | Inspire |
| Sanofi Pasteur INC. | $42.80 | 2023 | |
| Pfizer INC. | $42.73 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.64 | 2022 | |
| Ironshore Pharmaceuticals INC. | $37.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.52 | 2022-2025 | |
| Almatica Pharma LLC | $36.20 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.70 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $30.02 | 2019-2023 | Spravato |
| Globus Medical, INC. | $27.65 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $23.04 | 2020 | |
| Axsome Therapeutics, INC. | $20.39 | 2025 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $18.06 | 2022 | |
| Nevro Corp. | $16.28 | 2024 | Senza |
| Shire North American Group INC | $14.59 | 2019 | |
| Ibsa Pharma INC. | $12.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karsten Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.